Gamma knife radiosurgery for brain metastases from renal cell carcinoma with sorafenib and/or sunitinib therapyKeywords: brain metastasis, gamma knife, renal cancer, radiosurgery, outcomeInteractive Manuscript
Ask Questions of this Manuscript:
What is the background behind your study?
The high incidence of intracerebral hemorrhage (ICH) is reported in patients with metastatic renal cell carcinoma (RCC) treated with the tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
What is the purpose of your study?
We retrospectively evaluated effectiveness and safety of gamma knife radiosurgery (GKS) for the treatment of brain metastases from RCC with sorafenib and/or sunitinib therapy.
Describe your patient group.
The mean patient age was 59.6 (range 42-79), and the Karnofsky Performance Scale score was 100 in all ptients. Two patients (40%) had solitary brain metastasis. All patients had extracranial diseases and received systemic anti-angiogenetic therapies. One patient was treated with sorafenib, 3 patients with sunitinib and 1 patient with both sunitinib and sequential sorafenib.
Describe what you did.
Between July 2010 and June 2011, 5 patients (2 men and 3 women) with brain metastases from RCC were treated with GKS and followed up. The mean tumor volume was 0.5cm3 (range 0.001–2.6 cm3), and the mean marginal dose prescribed was 20.9Gy (range 17–22Gy) at the 50% isodose line.
Describe your main findings.
The mean follow-up period was 5.6 months (range 3-10 months). All of the 10 treated tumors were controlled (tumor disappearance, 40%; tumor regression, 50%; and stable disease, 10%). Repeated GKS for newly developed lesion was conducted in one patient. No patient developed radiation necrosis and ICH.
Describe the main limitation of this study.
This was a retrospective review.
Describe your main conclusion.
GKS seems to be a safe and effective treatment for brain metastases from RCC with sorafenib and/or sunitinib therapy for a short term.
Describe the importance of your findings and how they can be used by others.
Longer-term follow-up is indispensable and more data is required.
The high incidence of intracerebral hemorrhage (ICH) is reported in patients with metastatic renal cell carcinoma (RCC) treated with the tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
We retrospectively evaluated effectiveness and safety of gamma knife radiosurgery (GKS) for the treatment of brain metastases from RCC with sorafenib and/or sunitinib therapy.
The mean patient age was 59.6 (range 42-79), and the Karnofsky Performance Scale score was 100 in all ptients. Two patients (40%) had solitary brain metastasis. All patients had extracranial diseases and received systemic anti-angiogenetic therapies. One patient was treated with sorafenib, 3 patients with sunitinib and 1 patient with both sunitinib and sequential sorafenib.
Between July 2010 and June 2011, 5 patients (2 men and 3 women) with brain metastases from RCC were treated with GKS and followed up. The mean tumor volume was 0.5cm3 (range 0.001–2.6 cm3), and the mean marginal dose prescribed was 20.9Gy (range 17–22Gy) at the 50% isodose line.
The mean follow-up period was 5.6 months (range 3-10 months). All of the 10 treated tumors were controlled (tumor disappearance, 40%; tumor regression, 50%; and stable disease, 10%). Repeated GKS for newly developed lesion was conducted in one patient. No patient developed radiation necrosis and ICH.
This was a retrospective review.
GKS seems to be a safe and effective treatment for brain metastases from RCC with sorafenib and/or sunitinib therapy for a short term.
Longer-term follow-up is indispensable and more data is required.
Project Roles:
